Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Catalent shares jump on Q1 earnings beat, revenue forecast

Published Nov 16, 2023 06:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
CTLT
-0.30%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

SOMERSET, NJ - Catalent Inc . (NYSE:CTLT), a key player in pharmaceutical development and manufacturing, saw its shares surge approximately 12% today after announcing first-quarter financial results that surpassed analysts' expectations, despite a year-over-year decline in revenue.

The New Jersey-based company reported a net revenue of $982 million for the quarter, which was above the consensus estimate by $42.4 million but marked a roughly 4% decrease from the same period last year. This drop reflects a continuing trend, as the company has faced an average top-line contraction of about 14% over the past three quarters due to reduced COVID-era production demand.

Catalent played a pivotal role during the pandemic, providing crucial filling and packaging services for Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA)'s COVID-19 vaccines. As the surge in demand related to the pandemic wanes, CEO Alessandro Maselli has highlighted the company's efforts to return to pre-COVID operational levels.

Despite the overall decline in revenue, Catalent's non-COVID-related sales actually saw an increase of approximately 5% year-over-year. The biologics segment contributed $447 million to the top line but experienced an organic revenue drop of around 16% compared to last year, which is notably less severe than the approximately 37% year-over-year decline observed in Q4 FY23.

The company also reported adjusted EBITDA of $115 million for the quarter, which was down nearly 38% from last year but still exceeded forecasts sourced from Bloomberg by about $15.7 million. The reported net loss of $715 million was primarily due to $700 million in non-cash goodwill impairment charges, which have also delayed the filing of Catalent's 10-Q report.

Earlier today, Catalent's stock witnessed an impressive pre-market rise of nearly 5%, propelled by these quarterly results that exceeded market expectations. However, it's important to note that Catalent is managing significant financial leverage with substantial debt amounting to $4.95 billion and a high net leverage ratio of 7.4x.

Looking ahead to Fiscal Year 2024, Catalent has set a net revenue target range between $4.3 billion and $4.5 billion and anticipates an adjusted net income between $113 million and $175 million. This guidance reflects the company's strategic direction amidst shifting market conditions post-pandemic.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Catalent shares jump on Q1 earnings beat, revenue forecast
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email